AstraZeneca sells US rights to RSV drug to Swedish firm for $1.5B
Sobi buys US rights to Synagis, currently the only drug approved for treating RSV, along with 50 percent of US earnings for its successor, the Phase II MEDI8897.
Sobi buys US rights to Synagis, currently the only drug approved for treating RSV, along with 50 percent of US earnings for its successor, the Phase II MEDI8897.